Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy
Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-01
Target enrollment:
Participant gender:
Summary
1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment.
2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.
Phase:
PHASE2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital